Product Pipeline

Preclinical Development:

Avian Influenza Vaccine
Annual Influenza Vaccine
Biodefense Vaccine


Personnel

Dr. Mark Backer, PhD. CEO
Prior to Vaxart, Dr. Backer served as Vice President, Technical Development with PDL BioPharma from 2001 to 2005. He was also founding Chairman and currently serves as a Director of Molecular Medicine BioServices, a contract development and manufacturing firm focused on viral-based vaccines and therapies. Prior to PDL, Dr. Backer held development and operations positions of increasing responsibility with Aviron (now MedImmune Vaccines), Systemix, IDEC Pharmaceuticals, and Eli Lilly. Dr. Backer’s industry experience began in 1978, when he was the seventh employee of Genentech and initiated its pilot manufacturing operations.

Dr. Sean Tucker, PhD. VP Research and Director of Immunology
Dr. Tucker’s expertise is in oral administration of gene-based vaccines and mucosal immunology. He has previously served as a principal investigator on an NIH SBIR grant for the purpose of exploring oral delivery (salivary gland) as a site for HIV vaccine delivery. Dr. Tucker previously held research and development positions of increasing responsbility at Genteric, SyStemix, and Dow Chemical. Recently published articles include: Mol Therapy 8:392 and Vaccine 22:2500

Dr. Ciaran Scallan, PhD. Senior Scientist
Dr. Scallan’s expertise is in molecular virology and assesment of immune responses to viral vectors. Recently published articles include: Blood 102:3919, Blood 102:2021 and Blood 107:1810

Dr. Debora Tingley, PhD. Scientist
Dr. Tingley’s expertise is in molecular biology and histology. Before coming to Vaxart, she held scientist positions at Incyte and Ciphergen.


Key Advisors

Prof. Richard Whitley, M.D.; Director, Division of Pediatric Infectious Diseases, and Co-Director, Center for Emerging Infections and Emergency Preparedness, University of Alabama at Birmingham.

Bill Wainwright, PhD. Former Director of Vaccine Development, Wyeth

Michael Finney PhD. Founder, MJ Research

James Frincke, PhD. Exec VP and CSO, Hollis-Eden Pharmaceuticals